Theriva Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TOVX research report →
About the company
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract.
- CEO
- Steven A. Shallcross
- IPO
- 2006
- Employees
- 20
- HQ
- Rockville, MD, US
Price Chart
- Market Cap
- $8.96M
- P/E
- -0.10
- P/S
- 29.86
- P/B
- 0.67
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
- Gross Margin
- 92.00%
- Op Margin
- -7245.00%
- Net Margin
- -7153.00%
- ROE
- -178.29%
- ROIC
- -76.19%
- Revenue
- $0 · 0.00%
- Net Income
- $-25,249,000 · 1.57%
- EPS
- $-2.08 · 89.07%
- Op Income
- $-15,020,000
- FCF YoY
- 1.38%
- 52W High
- $0.86
- 52W Low
- $0.16
- 50D MA
- $0.30
- 200D MA
- $0.27
- Beta
- 1.09
- Avg Volume
- 20.74M
Get TickerSpark's AI analysis on TOVX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 26 | SHALLCROSS STEVEN A | other | 475,000 |
| Jan 5, 26 | MONAHAN JOHN J | other | 75,000 |
| Jan 5, 26 | Kraws Jeffrey J | other | 75,000 |
| Jan 5, 26 | Wolf Jeffrey Alan | other | 75,000 |
| Apr 29, 25 | Wolf Jeffrey Alan | other | 25,000 |
| Apr 29, 25 | SHALLCROSS STEVEN A | other | 190,000 |
| Apr 29, 25 | MONAHAN JOHN J | other | 25,000 |
| Apr 29, 25 | Kraws Jeffrey J | other | 25,000 |
| Dec 14, 23 | SHALLCROSS STEVEN A | other | 700,000 |
| Dec 14, 23 | Wolf Jeffrey Alan | other | 110,000 |
Our TOVX coverage
Recent articles, reports, and earnings notes.
No research on TOVX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TOVX report →Similar companies
Peers in the same neighborhood.